20.65
+0.56(+2.79%)
Currency In USD
| Previous Close | 20.09 |
| Open | 20.13 |
| Day High | 21.09 |
| Day Low | 19.63 |
| 52-Week High | 29.72 |
| 52-Week Low | 6.36 |
| Volume | 2.06M |
| Average Volume | 2.63M |
| Market Cap | 2.95B |
| PE | -5.7 |
| EPS | -3.62 |
| Moving Average 50 Days | 17.99 |
| Moving Average 200 Days | 13.04 |
| Change | 0.56 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $864.02 as of December 05, 2025 at a share price of $20.65. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 3 years ago, it would be worth $1,800.35 as of December 05, 2025 at a share price of $20.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
GlobeNewswire Inc.
Oct 06, 2025 10:01 PM GMT
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden reported by both p
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
GlobeNewswire Inc.
Oct 02, 2025 8:05 PM GMT
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the app
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Sep 29, 2025 12:35 PM GMT
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: